Synthesis and Evaluation of Novel Anticancer Compounds Derived from the Natural Product Brevilin A

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Cancer is a leading global cause of death, necessitating the development of more effective treatments.
• Brevilin A (BA) has demonstrated anticancer properties across various cancer types, highlighting its therapeutic potential.
• The chemical scaffold of brevilin A offers a promising basis for novel anticancer drug development.

Purpose of the Study:

• To design and synthesize novel brevilin A (BA) derivatives.
• To evaluate the anticancer efficacy of these new BA derivatives in various cancer cell lines.
• To identify specific BA derivatives with improved anticancer activity compared to the parent compound.

Main Methods:

• Synthesis of a library of 12 novel brevilin A (BA) derivatives.
• Structure-activity relationship (SAR) studies to assess anticancer effects.
• Evaluation of cancer cell viability, DNA damage, cell-cycle arrest, and apoptosis induction.

Main Results:

• Two novel BA derivatives, BA-9 and BA-10, exhibited significantly enhanced anticancer activity.
• BA-9 and BA-10 demonstrated superior efficacy against lung, colon, and breast cancer cell lines compared to brevilin A.
• These derivatives were more effective in reducing cancer cell viability and inducing DNA damage, cell-cycle arrest, and apoptosis.

Conclusions:

• Brevilin A derivatives BA-9 and BA-10 represent a significant advancement in the development of novel anticancer agents.
• The enhanced efficacy of BA-9 and BA-10 provides a strong foundation for further preclinical and clinical development.
• These findings underscore the potential of modified brevilin A scaffolds for future cancer therapies.